BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Special Report

Lynk Pharmaceuticals Delivers Breakthrough Phase Three Win For Oral Rheumatoid Arthritis Therapy

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development company focused on develop...

January 13, 2026 | News

Johnson And Johnson Amivantamab Combo Delivers 73% Response Rate In First Line Metastatic Colorectal Cancer

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable res...

January 12, 2026 | News

Ascletis Secures US FDA IND Clearance For Phase II Diabetes Study Of Oral GLP One Candidate ASC30

-The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the effi...

January 06, 2026 | News

2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know

At the centre of this momentum stood the U.S. Food and Drug Administration, whose 2025 approvals illustrated how medicine is moving decisiv...

December 29, 2025 | Analysis | By arcilla.fran@biopharmaapac.com

BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025

The year 2025 has marked a pivotal moment for the biopharmaceutical industry as it reckons with the aftershocks of a global pandemic and ongoing geopolitic...

December 24, 2025 | Analysis

Promontory Therapeutics Exceeds Interim Efficacy Bar In Thymoma Study With PT 112

Three of the first 10 patients with thymoma evaluated by RECIST have partial responses. Findings exceed protocol requirement of two re...

December 24, 2025 | News

Merck Secures World First Regulatory Approval For Pimicotinib In Rare Joint Tumour TGCT In China

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER study In MANEUVER, pimicotinib significantl...

December 23, 2025 | News

Atom Therapeutics Secures FDA Approval To Advance Phase II Trial Of ABP 745 In Atherosclerosis

Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, today announced FDA ...

December 18, 2025 | News

AusperBio Reports 30% Functional Cure Rate With AHB 137 In Chronic Hepatitis B

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing oli...

December 16, 2025 | Report

APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage

APAC Biopharma in Review: What Truly Moved the Needle This Year Asia-Pacific (APAC) has cemented its status as a pivotal biopharmaceutical hub in 2025, ma...

December 15, 2025 | Report

Top 25 Biotech Innovations Redefining Health And Planet In 2025

Biotechnology in 2025 is no longer confined to the laboratory bench. It is curing inherited blood disorders, changing how we prevent HIV, reimagining Alzhe...

December 10, 2025 | Report | By BioPharma APAC Wrap Up 2025

Aurigene Oncology Reports Strong Early Phase One Results For AUR112 In Relapsed And Refractory Lymphomas

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, announced initial clinical results...

December 04, 2025 | News

Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs

An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support...

November 27, 2025 | Report

The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech

Global pharmaceutical companies are racing to tap China’s new AI-powered biotech platforms to discover drugs faster and cheaper. In 2025, major Weste...

November 27, 2025 | Analysis

Stay Connected